PITTSBURGH, Dec. 10, 2014 /PRNewswire/ -- Mylan Inc.
(Nasdaq: MYL) today announced the U.S. launch of its Celecoxib
Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first
available generic versions of Pfizer's Celebrex®
Capsules, which is indicated for the relief of the signs and
symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing
spondylitis, and for the management of acute pain in adults.(1)
Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, had U.S.
sales of approximately $2.5 billion
for the 12 months ending September 30,
2014, according to IMS Health.
Currently, Mylan has 286 ANDAs pending FDA approval representing
$111.6 billion in annual brand sales,
according to IMS Health. Forty-five of these pending ANDAs are
potential first-to-file opportunities, representing $29.5 billion in annual brand sales, for the 12
months ending June 30, 2014,
according to IMS Health.
Mylan is a global pharmaceutical company committed to setting
new standards in health care. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several
brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. Learn more at
mylan.com.
(1) Celecoxib Capsules may cause an increased risk of
serious cardiovascular thrombotic events, myocardial infarction and
strokes. It may also increase the risk of gastrointestinal
bleeding, ulceration and perforation of the stomach or
intestines.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-launches-one-of-first-available-generic-versions-of-celebrex-capsules-300007622.html
SOURCE Mylan Inc.